Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
These antibodies are used to treat metastatic (spread) breast cancer. It is effective against tumors that overexpress the HER2/neu protein.
LPI (LP Information)' newest research report, the “Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Industry Forecast” looks at past sales and reviews total world Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer sales in 2022, providing a comprehensive analysis by region and market sector of projected Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer sales for 2023 through 2029. With Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer industry.
This Insight Report provides a comprehensive analysis of the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer.
The global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer players cover Roche, BOC Sciences, LGM Pharma, Biotechnica Pharma Global, KinBio and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
These antibodies are used to treat metastatic (spread) breast cancer. It is effective against tumors that overexpress the HER2/neu protein.
LPI (LP Information)' newest research report, the “Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Industry Forecast” looks at past sales and reviews total world Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer sales in 2022, providing a comprehensive analysis by region and market sector of projected Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer sales for 2023 through 2029. With Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer industry.
This Insight Report provides a comprehensive analysis of the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer.
The global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer players cover Roche, BOC Sciences, LGM Pharma, Biotechnica Pharma Global, KinBio and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Pertuzumab
- Trastuzumab
- Combination Therapy
- Mono Therapy
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- BOC Sciences
- LGM Pharma
- Biotechnica Pharma Global
- KinBio
- Merck
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2018-2029
2.1.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Segment by Type
2.2.1 Pertuzumab
2.2.2 Trastuzumab
2.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type
2.3.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
2.4 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Segment by Application
2.4.1 Combination Therapy
2.4.2 Mono Therapy
2.5 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application
2.5.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
3 MONO-ANTIBODY (MAB) FOR HER2-POSITIVE ADVANCED BREAST CANCER MARKET SIZE BY PLAYER
3.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Players
3.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Players (2018-2023)
3.1.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Players (2018-2023)
3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 MONO-ANTIBODY (MAB) FOR HER2-POSITIVE ADVANCED BREAST CANCER BY REGIONS
4.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Regions (2018-2023)
4.2 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth (2018-2023)
4.3 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth (2018-2023)
4.4 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth (2018-2023)
4.5 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2018-2023)
5.2 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023)
5.3 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2018-2023)
6.2 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023)
6.3 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Country (2018-2023)
7.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023)
7.3 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Region (2018-2023)
8.2 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023)
8.3 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL MONO-ANTIBODY (MAB) FOR HER2-POSITIVE ADVANCED BREAST CANCER MARKET FORECAST
10.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Regions (2024-2029)
10.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Regions (2024-2029)
10.1.2 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast
10.1.3 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast
10.1.4 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast
10.1.5 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast
10.2 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Country (2024-2029)
10.2.1 United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.2.2 Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.2.3 Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.2.4 Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Region (2024-2029)
10.3.1 China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3.2 Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3.3 Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3.4 Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3.5 India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3.6 Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.4 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Country (2024-2029)
10.4.1 Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.4.2 France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.4.3 UK Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.4.4 Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.4.5 Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.5 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Region (2024-2029)
10.5.1 Egypt Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.5.2 South Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.5.3 Israel Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.5.4 Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.5.5 GCC Countries Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.6 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Type (2024-2029)
10.7 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.1.3 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 BOC Sciences
11.2.1 BOC Sciences Company Information
11.2.2 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.2.3 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 BOC Sciences Main Business Overview
11.2.5 BOC Sciences Latest Developments
11.3 LGM Pharma
11.3.1 LGM Pharma Company Information
11.3.2 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.3.3 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 LGM Pharma Main Business Overview
11.3.5 LGM Pharma Latest Developments
11.4 Biotechnica Pharma Global
11.4.1 Biotechnica Pharma Global Company Information
11.4.2 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.4.3 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Biotechnica Pharma Global Main Business Overview
11.4.5 Biotechnica Pharma Global Latest Developments
11.5 KinBio
11.5.1 KinBio Company Information
11.5.2 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.5.3 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 KinBio Main Business Overview
11.5.5 KinBio Latest Developments
11.6 Merck
11.6.1 Merck Company Information
11.6.2 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.6.3 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Merck Main Business Overview
11.6.5 Merck Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2018-2029
2.1.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Segment by Type
2.2.1 Pertuzumab
2.2.2 Trastuzumab
2.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type
2.3.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
2.4 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Segment by Application
2.4.1 Combination Therapy
2.4.2 Mono Therapy
2.5 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application
2.5.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
3 MONO-ANTIBODY (MAB) FOR HER2-POSITIVE ADVANCED BREAST CANCER MARKET SIZE BY PLAYER
3.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Players
3.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Players (2018-2023)
3.1.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Players (2018-2023)
3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 MONO-ANTIBODY (MAB) FOR HER2-POSITIVE ADVANCED BREAST CANCER BY REGIONS
4.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Regions (2018-2023)
4.2 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth (2018-2023)
4.3 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth (2018-2023)
4.4 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth (2018-2023)
4.5 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2018-2023)
5.2 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023)
5.3 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2018-2023)
6.2 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023)
6.3 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Country (2018-2023)
7.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023)
7.3 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Region (2018-2023)
8.2 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023)
8.3 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL MONO-ANTIBODY (MAB) FOR HER2-POSITIVE ADVANCED BREAST CANCER MARKET FORECAST
10.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Regions (2024-2029)
10.1.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Regions (2024-2029)
10.1.2 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast
10.1.3 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast
10.1.4 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast
10.1.5 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast
10.2 Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Country (2024-2029)
10.2.1 United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.2.2 Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.2.3 Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.2.4 Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3 APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Region (2024-2029)
10.3.1 China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3.2 Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3.3 Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3.4 Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3.5 India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.3.6 Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.4 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Country (2024-2029)
10.4.1 Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.4.2 France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.4.3 UK Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.4.4 Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.4.5 Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.5 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Region (2024-2029)
10.5.1 Egypt Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.5.2 South Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.5.3 Israel Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.5.4 Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.5.5 GCC Countries Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast
10.6 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Type (2024-2029)
10.7 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.1.3 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 BOC Sciences
11.2.1 BOC Sciences Company Information
11.2.2 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.2.3 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 BOC Sciences Main Business Overview
11.2.5 BOC Sciences Latest Developments
11.3 LGM Pharma
11.3.1 LGM Pharma Company Information
11.3.2 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.3.3 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 LGM Pharma Main Business Overview
11.3.5 LGM Pharma Latest Developments
11.4 Biotechnica Pharma Global
11.4.1 Biotechnica Pharma Global Company Information
11.4.2 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.4.3 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Biotechnica Pharma Global Main Business Overview
11.4.5 Biotechnica Pharma Global Latest Developments
11.5 KinBio
11.5.1 KinBio Company Information
11.5.2 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.5.3 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 KinBio Main Business Overview
11.5.5 KinBio Latest Developments
11.6 Merck
11.6.1 Merck Company Information
11.6.2 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
11.6.3 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Merck Main Business Overview
11.6.5 Merck Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Pertuzumab
Table 3. Major Players of Trastuzumab
Table 4. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Table 7. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Table 10. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Player (2018-2023)
Table 12. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Key Players Head office and Products Offered
Table 13. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Regions (2018-2023)
Table 18. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Country (2018-2023)
Table 22. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Table 24. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Table 26. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Region (2018-2023)
Table 28. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Table 30. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Table 32. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Country (2018-2023)
Table 34. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Table 36. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer
Table 45. Key Market Challenges & Risks of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer
Table 46. Key Industry Trends of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer
Table 47. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. Roche Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 52. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 53. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. Roche Main Business
Table 55. Roche Latest Developments
Table 56. BOC Sciences Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 57. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 58. BOC Sciences Main Business
Table 59. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. BOC Sciences Latest Developments
Table 61. LGM Pharma Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 62. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 63. LGM Pharma Main Business
Table 64. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. LGM Pharma Latest Developments
Table 66. Biotechnica Pharma Global Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 67. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 68. Biotechnica Pharma Global Main Business
Table 69. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. Biotechnica Pharma Global Latest Developments
Table 71. KinBio Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 72. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 73. KinBio Main Business
Table 74. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. KinBio Latest Developments
Table 76. Merck Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 77. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 78. Merck Main Business
Table 79. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Merck Latest Developments
Table 1. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Pertuzumab
Table 3. Major Players of Trastuzumab
Table 4. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Table 7. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Table 10. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Player (2018-2023)
Table 12. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Key Players Head office and Products Offered
Table 13. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Regions (2018-2023)
Table 18. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Country (2018-2023)
Table 22. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Table 24. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Table 26. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Region (2018-2023)
Table 28. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Table 30. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Table 32. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Country (2018-2023)
Table 34. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Table 36. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer
Table 45. Key Market Challenges & Risks of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer
Table 46. Key Industry Trends of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer
Table 47. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. Roche Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 52. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 53. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. Roche Main Business
Table 55. Roche Latest Developments
Table 56. BOC Sciences Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 57. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 58. BOC Sciences Main Business
Table 59. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. BOC Sciences Latest Developments
Table 61. LGM Pharma Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 62. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 63. LGM Pharma Main Business
Table 64. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. LGM Pharma Latest Developments
Table 66. Biotechnica Pharma Global Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 67. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 68. Biotechnica Pharma Global Main Business
Table 69. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. Biotechnica Pharma Global Latest Developments
Table 71. KinBio Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 72. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 73. KinBio Main Business
Table 74. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. KinBio Latest Developments
Table 76. Merck Details, Company Type, Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served and Its Competitors
Table 77. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Offered
Table 78. Merck Main Business
Table 79. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Merck Latest Developments
LIST OF FIGURES
Figure 1. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country/Region (2022)
Figure 8. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type in 2022
Figure 10. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in Combination Therapy
Figure 11. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Combination Therapy (2018-2023) & ($ Millions)
Figure 12. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in Mono Therapy
Figure 13. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Mono Therapy (2018-2023) & ($ Millions)
Figure 14. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application in 2022
Figure 15. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Player in 2022
Figure 16. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Regions (2018-2023)
Figure 17. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 18. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 19. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 20. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 21. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Value Market Share by Country in 2022
Figure 22. United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 23. Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 24. Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 25. Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 26. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Region in 2022
Figure 27. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type in 2022
Figure 28. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application in 2022
Figure 29. China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 30. Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 31. Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 32. Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 33. India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 34. Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 35. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Country in 2022
Figure 36. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Figure 37. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Figure 38. Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 39. France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 40. UK Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 41. Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 42. Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 43. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Region (2018-2023)
Figure 44. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Figure 45. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Figure 46. Egypt Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 47. South Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 48. Israel Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 49. Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 50. GCC Country Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 51. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 52. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 53. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 54. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 55. United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 56. Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 57. Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 58. Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 59. China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 60. Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 61. Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 62. Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 63. India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 64. Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 65. Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 66. France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 67. UK Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 68. Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 69. Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 70. Spain Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 71. Egypt Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 72. South Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 73. Israel Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 74. Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 75. GCC Countries Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 76. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share Forecast by Type (2024-2029)
Figure 77. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country/Region (2022)
Figure 8. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type in 2022
Figure 10. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in Combination Therapy
Figure 11. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Combination Therapy (2018-2023) & ($ Millions)
Figure 12. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in Mono Therapy
Figure 13. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Mono Therapy (2018-2023) & ($ Millions)
Figure 14. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application in 2022
Figure 15. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Player in 2022
Figure 16. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Regions (2018-2023)
Figure 17. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 18. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 19. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 20. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 21. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Value Market Share by Country in 2022
Figure 22. United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 23. Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 24. Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 25. Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 26. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Region in 2022
Figure 27. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type in 2022
Figure 28. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application in 2022
Figure 29. China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 30. Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 31. Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 32. Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 33. India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 34. Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 35. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Country in 2022
Figure 36. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Figure 37. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Figure 38. Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 39. France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 40. UK Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 41. Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 42. Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 43. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Region (2018-2023)
Figure 44. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Type (2018-2023)
Figure 45. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share by Application (2018-2023)
Figure 46. Egypt Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 47. South Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 48. Israel Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 49. Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 50. GCC Country Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 51. Americas Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 52. APAC Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 53. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 54. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 55. United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 56. Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 57. Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 58. Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 59. China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 60. Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 61. Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 62. Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 63. India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 64. Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 65. Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 66. France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 67. UK Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 68. Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 69. Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 70. Spain Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 71. Egypt Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 72. South Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 73. Israel Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 74. Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 75. GCC Countries Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 76. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share Forecast by Type (2024-2029)
Figure 77. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Market Share Forecast by Application (2024-2029)
